AVTRAvantor, Inc.

$15.67+25% 1Y

$15.67

$7.4152 weeks$15.85

AVTR in its own filings

AVTR's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

166

Events found in the filings · across 779 filings · the record starts in 2019

Hard flags: 1
Hard flags
Most recent filing: Sep 21, 2026
Most recent filing · Form 8-K
Record starts: Mar 7, 2019
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 28, 2026
Delisting notice / listing-rule failurehistorical: 2022-05-17
Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares: 2022-05-31
SEC comment-letter activity16 occurrences: 2020-05-18

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 21, 2026On September 21, 2026, Avantor, Inc. (the “Company”), announced the appointment of Todd Garner as Executive Vice President and Chief Financial Officer, effective as of September 21, 2026 (the “Commencement Date”)Director or officer change · Form 8-K
Sep 21, 2026On September 21, 2026, Avantor, Inc. (the “Company”), announced the appointment of Todd Garner as Executive Vice President and Chief Financial Officer, effective as of September 21, 2026 (the “Commencement Date”)Director or officer change · Form 8-K
Aug 27, 2026On April 23, 2026, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) disclosing that Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, would transition to a new role supporting the Company’s segment integration activities for a period of time …Director or officer change · Form 8-K/A
Jul 29, 2026Avantor® Reports Second Quarter 2026 Results.Earnings release · press release
Jul 17, 2026On July 14, 2026 (the “Effective Date”), Avantor Funding, Inc. (the “Borrower”), a wholly owned subsidiary of Avantor, Inc. (the “Company”), entered into Amendment No. 15 to Credit Agreement (the “Credit Agreement Amendment”), which amended that certain Credit Agreement, originally dated as of November 21, 2017 (as …Material agreement entered · Form 8-K
Apr 29, 2026Avantor® Reports First Quarter 2026 Results.Earnings release · press release
Apr 23, 2026On April 17, 2026, Avantor, Inc. (the “Company”) informed Benoit Gourdier, the Company’s Executive Vice President, Bioscience and Medtech Products, that he would be transitioning to a new role supporting the Company’s segment integration activities, after which it is expected that he would depart the Company no later …Director or officer change · Form 8-K
Apr 1, 2026On March 26, 2026, Mr. R. Brent Jones notified Avantor, Inc. (the “Company”) of his decision to resign as the Company’s Executive Vice President and Chief Financial Officer (“CFO”) to join a company outside the life sciences industry.Director or officer change · Form 8-K
Feb 25, 2026On December 17, 2025, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K announcing the election of Simon Dingemans as a director of the Company effective January 2, 2026.Director or officer change · Form 8-K/A
Feb 25, 2026On December 4, 2025, Avantor, Inc. (the “Company”) filed a Current Report on Form 8-K announcing the election of Sanjeev Mehra as a director of the Company effective December 4, 2025.Director or officer change · Form 8-K/A
Feb 11, 2026Avantor® Reports Fourth Quarter and Full Year 2025 Results.Earnings release · press release